← 返回

细胞因子偶联以增强 T 细胞治疗

英文原题:Cytokine conjugation to enhance T cell therapy.

查看英文原题

Cytokine conjugation to enhance T cell therapy.

PubMed 2022/12/28(内容时间) Proc Natl Acad Sci U S A Q1 · IF 9.5(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

过继T细胞转移(ACT)疗法存在多项局限,例如对实体瘤控制不佳。ACT联合细胞因子治疗虽然可能提高疗效,但也会引起显著副作用。本文介绍一种纳米技术方法:在制造过程中利用非天然糖纳米颗粒对T细胞进行代谢标记,从而将抗肿瘤细胞因子直接偶联到T细胞表面,以提高ACT疗效。该方法可使原本具有毒性的细胞因子在局部高浓度发挥作用。它能够增加T细胞向实体瘤浸润,促使宿主免疫系统产生I型免疫应答,促进抗原扩展,并改善对侵袭性实体瘤的控制;此外,即使CAR-T 细胞剂量不足以单独治愈血液癌症,该方法仍可促成肿瘤完全消退。总体而言,这种方法有效且易于整合至现有ACT生产流程,有望在多种治疗情境中提高疗效。

展开英文摘要原文

Adoptive T cell transfer (ACT) therapies suffer from a number of limitations (e. g. , poor control of solid tumors), and while combining ACT with cytokine therapy can enhance effectiveness, this also results in significant side effects.

Here, we describe a nanotechnology approach to improve the efficacy of ACT therapies by metabolically labeling T cells with unnatural sugar nanoparticles, allowing direct conjugation of antitumor cytokines onto the T cell surface during the manufacturing process. This allows local, concentrated activity of otherwise toxic cytokines.

This approach increases T cell infiltration into solid tumors, activates the host immune system toward a Type 1 response, encourages antigen spreading, and improves control of aggressive solid tumors and achieves complete blood cancer regression with otherwise noncurative doses of CAR-T cells.

Overall, this method provides an effective and easily integrated approach to the current ACT manufacturing process to increase efficacy in various settings.

论文信息

作者
Liu Y、Adu-Berchie K、Brockman JM、Pezone M、Zhang DKY、Zhou J、Pyrdol JW、Wang H
单位
John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge, MA 02138.United Kingdom
文献类型
美国 NIH 资助研究 · 非美国政府资助研究 · 美国公共卫生署资助研究
期刊
Proceedings of the National Academy of Sciences of the United States of America2023 Jan 3
原文标识
PubMed 36577059 · DOI 10.1073/pnas.2213222120